245 related articles for article (PubMed ID: 20562910)
1. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
2. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
[TBL] [Abstract][Full Text] [Related]
3. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
[TBL] [Abstract][Full Text] [Related]
4. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression.
Li H; Wang Y; Liu X
J Biol Chem; 2008 Mar; 283(10):6209-21. PubMed ID: 18171681
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha controls the decatenation checkpoint.
Luo K; Yuan J; Chen J; Lou Z
Nat Cell Biol; 2009 Feb; 11(2):204-10. PubMed ID: 19098900
[TBL] [Abstract][Full Text] [Related]
6. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
7. Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chromosomal destabilization.
Kaufmann WK; Campbell CB; Simpson DA; Deming PB; Filatov L; Galloway DA; Zhao XJ; Creighton AM; Downes CS
Cell Cycle; 2002; 1(3):210-9. PubMed ID: 12429935
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the topoisomerase II-dependent decatenation G2 checkpoint and checkpoint kinases in human cells.
Kaufmann WK
Methods Mol Biol; 2009; 582():155-66. PubMed ID: 19763949
[TBL] [Abstract][Full Text] [Related]
9. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.
Nakagawa T; Hayashita Y; Maeno K; Masuda A; Sugito N; Osada H; Yanagisawa K; Ebi H; Shimokata K; Takahashi T
Cancer Res; 2004 Jul; 64(14):4826-32. PubMed ID: 15256452
[TBL] [Abstract][Full Text] [Related]
10. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
11. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
12. BAF complexes facilitate decatenation of DNA by topoisomerase IIα.
Dykhuizen EC; Hargreaves DC; Miller EL; Cui K; Korshunov A; Kool M; Pfister S; Cho YJ; Zhao K; Crabtree GR
Nature; 2013 May; 497(7451):624-7. PubMed ID: 23698369
[TBL] [Abstract][Full Text] [Related]
13. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line.
Carpenter AJ; Porter AC
Mol Biol Cell; 2004 Dec; 15(12):5700-11. PubMed ID: 15456904
[TBL] [Abstract][Full Text] [Related]
14. Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation.
Kratz AS; Richter KT; Schlosser YT; Schmitt M; Shumilov A; Delecluse HJ; Hoffmann I
Cell Cycle; 2016 Dec; 15(24):3419-3431. PubMed ID: 27754753
[TBL] [Abstract][Full Text] [Related]
15. The human decatenation checkpoint.
Deming PB; Cistulli CA; Zhao H; Graves PR; Piwnica-Worms H; Paules RS; Downes CS; Kaufmann WK
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12044-9. PubMed ID: 11593014
[TBL] [Abstract][Full Text] [Related]
16. NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M transition through the regulation of a TOPOIIα-mediated decatenation checkpoint.
Ando K; Ozaki T; Hirota T; Nakagawara A
PLoS One; 2013; 8(12):e82744. PubMed ID: 24349352
[TBL] [Abstract][Full Text] [Related]
17. MCPH1 Lack of Function Enhances Mitotic Cell Sensitivity Caused by Catalytic Inhibitors of Topo II.
Arroyo M; Sánchez A; Cañuelo A; Heredia-Molina RF; Martínez-Molina E; Clarke DJ; Marchal JA
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32276518
[TBL] [Abstract][Full Text] [Related]
18. RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progression.
Ramamoorthy M; Tadokoro T; Rybanska I; Ghosh AK; Wersto R; May A; Kulikowicz T; Sykora P; Croteau DL; Bohr VA
Nucleic Acids Res; 2012 Feb; 40(4):1621-35. PubMed ID: 22013166
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 participates in DNA decatenation.
Lou Z; Minter-Dykhouse K; Chen J
Nat Struct Mol Biol; 2005 Jul; 12(7):589-93. PubMed ID: 15965487
[TBL] [Abstract][Full Text] [Related]
20. Defective decatenation checkpoint function is a common feature of melanoma.
Brooks K; Chia KM; Spoerri L; Mukhopadhyay P; Wigan M; Stark M; Pavey S; Gabrielli B
J Invest Dermatol; 2014 Jan; 134(1):150-158. PubMed ID: 23842115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
